Geneoscopy
St. Louis, United States · Biotechnology, Healthcare, Health Care
Geneoscopy is a life sciences company with the mission to empower patients and providers to transform gastrointestinal health through innovative diagnostics. Geneoscopy’s lead diagnostic uses stool-derived eukaryotic RNA (seRNA) to detect colorectal cancer and precancerous adenomas. This device was awarded a Breakthrough Device Designation from the FDA for its ability to reduce morbidity associate
Key facts
- Headquarters
- St. Louis, United States
- Employees
- 63
- Industries
- Biotechnology, Healthcare, Health Care
- Status
- Private
- Website
- geneoscopy.com
- Company page
Recent activity at Geneoscopy
- : Geneoscopy Appoints Amit Bhalla as Chief Financial Officer
- : Geneoscopy, Inc. raised $105 million in a Series C funding round led by Bio-Rad Laboratories to advance their at-home colorectal cancer screening test, ColoSense.
- : Geneoscopy Appoints Matt Sargent as Chief Commercial Officer and Tyler Aldredge as Vice President of Operations
- : Geneoscopy, Inc.
- : Geneoscopy Closes $105M In Financing To Advance Its Noninvasive Multifactor Rna Screening Test For Colorectal Cancer Prevention
- : Geneoscopy, Inc.
Geneoscopy funding history
| Date | Round | Amount |
|---|---|---|
| Jan 2025 | Series C | $105.0M |
| Nov 2021 | Venture | $50.5M |
| Nov 2021 | Funding Round | $105.0M |
| Sep 2019 | Venture | $7.9M |
Leadership
- ANDREW BARNELL, Executive Officer, Director
- Amit Bhalla, Chief Financial Officer
- Erica Barnell, Chief Medical Officer
- Matt Sargent, Chief Commercial Officer
Verified email and direct lines for Geneoscopy ’s decision-makers are on Fundz. See plans
Employee benefit plans
Geneoscopy files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Geneoscopy in the news
- Test Included as a Preferred Option in the American Cancer Society Colorectal Cancer Screening Guidelines Update - Business Wire (May 27, 2026)
- CMS Grants Medicare Coverage for ColoSense®, Expanding Access to Simplified Noninvasive Colorectal Cancer Screening - Business Wire (Jun 08, 2026)
- Labcorp Announces Nationwide Availability of ColoSense®, the First FDA-Approved RNA-Based At-Home Colorectal Cancer Screening Test - PR Newswire (Jun 22, 2026)
- Geneoscopy Wins Second Patent Trial and Appeal Board Decision, Invalidating All Challenged Claims of Exact Sciences’ ’746 Patent - Business Wire (Feb 06, 2026)
- St. Louis Business 500: Q&A with Andrew Barnell, Geneoscopy - St. Louis Magazine (Feb 25, 2026)
- Geneoscopy’s New FDA-Approved Stool Collection Method Simplifies At-Home Colorectal Cancer Screening - BioSpace (Jul 24, 2025)
- Geneoscopy RNA-Based Colorectal Cancer Test Now Available Nationwide Through Labcorp - insights.citeline.com (Jun 26, 2026)
- Fire Awards 2025: Geneoscopy secures $105M to expand gastrointestinal health diagnostics - The Business Journals (Jul 10, 2025)
Companies similar to Geneoscopy
- Avalon Globocare Corp. · Biotechnology, Healthcare, Health Care, Health Diagnostics, Therapeutics
- Pictor · Biotechnology, Health Care, Health Diagnostics, Therapeutics
- Biofrontera · Biotechnology, Healthcare, Health Care, Therapeutics
- Verrica · Biotechnology, Healthcare, Health Care, Therapeutics
- Passage Bio · Biotechnology, Healthcare, Health Care, Therapeutics
About Geneoscopy : questions and answers
What does Geneoscopy do?
Geneoscopy is a life sciences company with the mission to empower patients and providers to transform gastrointestinal health through innovative diagnostics. Geneoscopy’s lead diagnostic uses stool-derived eukaryotic RNA (seRNA) to detect colorectal cancer and precancerous adenomas. This device was awarded a Breakthrough Device Designation from the FDA for its ability to reduce morbidity associate
Where is Geneoscopy headquartered?
Geneoscopy is headquartered in St. Louis, United States.
How many employees does Geneoscopy have?
Geneoscopy has about 63 employees.
Has Geneoscopy raised funding?
Yes. Fundz has recorded 4 funding events for Geneoscopy . The most recent, Series C of $105.0M, was in Jan 2025.
What is the latest news on Geneoscopy ?
On Apr 02, 2025, Geneoscopy Appoints Amit Bhalla as Chief Financial Officer
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy